Abstract: The present disclosure relates to an anode electrode active material for a secondary battery containing nickel cobalt molybdenum oxide, an anode electrode for a secondary battery including the same, a secondary battery including the anode electrode for a secondary battery, and a method for manufacturing the same. The novel anode electrode material for a sodium secondary battery containing nickel cobalt molybdenum oxide according to the present disclosure allows intercalation/deintercalation reaction of sodium ion during charge/discharge and does not undergo significant volume change during the intercalation reaction because structure is maintained stably during repeated charge/discharge. As a result, electrode damage and electric short circuit are decreased and, thus, improved electrochemical characteristics can be achieved in long-life and high-rate capability.

Abstract: The present disclosure relates to an anode electrode active material for a secondary battery containing nickel cobalt molybdenum oxide, an anode electrode for a secondary battery including the same, a secondary battery including the anode electrode for a secondary battery, and a method for manufacturing the same. The novel anode electrode material for a sodium secondary battery containing nickel cobalt molybdenum oxide according to the present disclosure allows intercalation/deintercalation reaction of sodium ion during charge/discharge and does not undergo significant volume change during the intercalation reaction because structure is maintained stably during repeated charge/discharge. As a result, electrode damage and electric short circuit are decreased and, thus, improved electrochemical characteristics can be achieved in long-life and high-rate capability.

Abstract: The present disclosure relates to an anode electrode active material for a secondary battery containing nickel cobalt molybdenum oxide, an anode electrode for a secondary battery including the same, a secondary battery including the anode electrode for a secondary battery, and a method for manufacturing the same. The novel anode electrode material for a sodium secondary battery containing nickel cobalt molybdenum oxide according to the present disclosure allows intercalation/deintercalation reaction of sodium ion during charge/discharge and does not undergo significant volume change during the intercalation reaction because structure is maintained stably during repeated charge/discharge. As a result, electrode damage and electric short circuit are decreased and, thus, improved electrochemical characteristics can be achieved in long-life and high-rate capability.

Abstract: The present invention relates to a composition for treating eye diseases, wherein the composition comprises a pyrazole-based compound, which is a pharmacologically active substance, and a biodegradable polymer, so that a drug effectively reaches a posterior segment of an eyeball, while prolonging an action time of the drug administered into the eyeball.

Abstract: The present disclosure relates to an anode electrode active material for a secondary battery containing nickel cobalt molybdenum oxide, an anode electrode for a secondary battery including the same, a secondary battery including the anode electrode for a secondary battery, and a method for manufacturing the same. The novel anode electrode material for a sodium secondary battery containing nickel cobalt molybdenum oxide according to the present disclosure allows intercalation/deintercalation reaction of sodium ion during charge/discharge and does not undergo significant volume change during the intercalation reaction because structure is maintained stably during repeated charge/discharge. As a result, electrode damage and electric short circuit are decreased and, thus, improved electrochemical characteristics can be achieved in long-life and high-rate capability.

Abstract: Systems and methods for phase alignment among multiple transmitters are described. In some embodiments, a method may include creating a loop between an RF transmitter and an RF receiver; measuring a first DC signal on the I and Q paths of the RF receiver without inserting a DC signal in the I and Q paths of the RF transmitter; measuring a second DC signal on the I and Q paths of the RF receiver while inserting a non-zero DC signal in the I and Q paths of the RF transmitter; and calculating a relative phase difference between the RF transmitter and the RF receiver using the first and second DC signals.

Abstract: Systems and methods for phase alignment among multiple transmitters are described. In some embodiments, a method may include creating a loop between an RF transmitter and an RF receiver; measuring a first DC signal on the I and Q paths of the RF receiver without inserting a DC signal in the I and Q paths of the RF transmitter; measuring a second DC signal on the I and Q paths of the RF receiver while inserting a non-zero DC signal in the I and Q paths of the RF transmitter; and calculating a relative phase difference between the RF transmitter and the RF receiver using the first and second DC signals.

Abstract: Provided is a pharmaceutical combination preparation including fimasartan and rosuvastatin as active ingredients together with meglumine. The combination preparation exhibits an outstanding effect in treating cardiovascular disease by improving the disintegration and the dissolution which obtained better drug bioavailability and drug safety.

Abstract: Systems and methods for phase alignment among multiple transmitters are described. In some embodiments, a method may include creating a loop between an RF transmitter and an RF receiver; measuring a first DC signal on the I and Q paths of the RF receiver without inserting a DC signal in the I and Q paths of the RF transmitter; measuring a second DC signal on the I and Q paths of the RF receiver while inserting a non-zero DC signal in the I and Q paths of the RF transmitter; and calculating a relative phase difference between the RF transmitter and the RF receiver using the first and second DC signals.

Abstract: The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation, have superior content uniformity; and a preparation method thereof.

Abstract: The present invention relates to a pharmaceutical combination preparation comprising fimasartan and rosuvastatin as active ingredients together with meglumine. The combination preparation of the present invention exhibits an outstanding effect in treating cardiovascular disease by improving the disintegration and the dissolution which obtained better drug bioavailability and drug safety.

Abstract: The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation, have superior content uniformity; and a preparation method thereof.

Abstract: Provided is an antihypertensive pharmaceutical composition containing Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker, and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker.

Abstract: Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability.

Abstract: Provided is an antihypertensive pharmaceutical composition containing Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker, and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker.

Abstract: A security circuit using at least two finite state machine units for storing data to and reading data from a multiport memory in a pipelined manner and an intermediate memory, for facilitating transfer of data between the at least two finite state machines. The security circuit may be used to perform key setup and/or data ciphering faster. The security circuit may operate in any environment where the key is changed every frame, for example, a wireless LAN application and the security circuit may operate in conjunction with, or as part of, a MAC controller.

Abstract: A security circuit using at least two finite state machine units for storing data to and reading data from a multiport memory in a pipelined manner and an intermediate memory, for facilitating transfer of data between the at least two finite state machines. The security circuit may be used to perform key setup and/or data ciphering faster. The security circuit may operate in any environment where the key is changed every frame, for example, a wireless LAN application and the security circuit may operate in conjunction with, or as part of, a MAC controller.

Abstract: The present invention relates to electrochemical storage devices containing a non-aqueous lithium based electrolyte with high ionic conductivity, low impedance, and high thermal stability. More particularly, this invention relates to the design, synthesis and application of novel fluorinated arylboron oxalate based compounds which act as anion receptors and/or additives for non-aqueous batteries. When used as an anion receptor for non-aqueous battery electrolytes, the fluorinated arylboron oxalate enhances conductivity, lithium ion transference number and Solid Electrolyte Interface (SEI) formation capability during the formation cycling.

Abstract: The present invention provides an asymmetric hybrid capacitor, in which metal oxide containing lithium and capable of producing lithium ions by an electrochemical reaction and supplying the lithium ions in an electrolyte in the capacitor is used as a positive electrode active material, and metal oxide capable of accepting the lithium ions supplied through the electrolyte is used as a negative electrode active material, such that the lithium ions of the same participate in the electrochemical reactions at both electrodes. As a result, it is possible to minimize reduction in ionic conductivity during charge/discharge, compared with conventional asymmetric hybrid capacitors, in which metal oxide and a carbon material are used as electrode materials, respectively. Moreover, since metal oxide having high specific capacitance is used to form both electrodes, it is possible to maximize energy density and power density.

Abstract: The present invention relates to a cryptographic apparatus for encrypting data stored in a memory. The cryptographic apparatus of the present invention operates in the ECB, CBC, CBC-MAC, counter and OCB modes using small and simple elements. The cryptographic apparatus minimizes data communication between CPU and the cryptographic apparatus to improve the performance of the communication system. On the other hand, the input buffer and output buffer of the cryptographic apparatus are configured to store at least two blocks respectively, so that the performance of the cryptographic apparatus is maximized. Furthermore, the cryptographic apparatus supports zero-padding, so that the process of the CPU is minimized.